Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection

HPB (Oxford). 2016 Apr;18(4):360-6. doi: 10.1016/j.hpb.2015.11.003. Epub 2016 Feb 17.

Abstract

Background: Long-term incidence of endocrine and exocrine insufficiency after pancreatectomy is poorly described. We analyze the long-term risks of pancreatic insufficiency after pancreatectomy.

Methods: Subjects who underwent pancreatectomy from 2002 to 2012 were identified from a prospective database (n = 227). Subjects who underwent total pancreatectomy or pancreatitis surgery were excluded. New post-operative endocrine and exocrine insufficiency was defined as the need for new pharmacologic intervention within 1000 days from resection.

Results: 28 (16%) of 178 subjects without pre-existing endocrine insufficiency developed post-operative endocrine insufficiency: 7 (25%) did so within 30 days, 8 (29%) between 30 and 90 days, and 13 (46%) after 90 days. 94 (43%) of 214 subjects without pre-operative exocrine insufficiency developed exocrine insufficiency: 20 (21%) did so within 30 days, 29 (31%) between 30 and 90 days, and 45 (48%) after 90 days. Adjuvant radiation was associated with new endocrine insufficiency. On multivariate regression, pancreaticoduodenectomy and chemotherapy were associated with a greater risk of exocrine insufficiency.

Conclusion: Reporting 30-day functional outcomes for pancreatic resection is insufficient, as nearly 45% of subjects who develop disease do so after 90 days. Reporting of at least 90-day outcomes may more reliably assess risk for post-operative endocrine and exocrine insufficiency.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chemotherapy, Adjuvant / adverse effects
  • Databases, Factual
  • Exocrine Pancreatic Insufficiency / diagnosis
  • Exocrine Pancreatic Insufficiency / drug therapy
  • Exocrine Pancreatic Insufficiency / etiology*
  • Exocrine Pancreatic Insufficiency / physiopathology
  • Female
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Islets of Langerhans / drug effects
  • Islets of Langerhans / pathology
  • Islets of Langerhans / physiopathology
  • Islets of Langerhans / surgery*
  • Male
  • Middle Aged
  • Pancreas, Exocrine / drug effects
  • Pancreas, Exocrine / pathology
  • Pancreas, Exocrine / physiopathology
  • Pancreas, Exocrine / surgery*
  • Pancreatectomy / adverse effects*
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / surgery*
  • Pancreaticoduodenectomy / adverse effects*
  • Radiotherapy, Adjuvant / adverse effects
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Hypoglycemic Agents